Bailard’s Stemline Therapeutics, Inc. STML Stock Holding History

Bailard’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-64,600	Closed	-$717K	–	454
2017 Q3	$717K	Sell	64,600 -19,185	-23%	-$180K	0.06%	190
2017 Q2	$771K	Sell	83,785 -55,000	-40%	-$459K	0.06%	186
2017 Q1	$1.19M	Buy	138,785 +15,000	+12%	+$137K	0.1%	162
2016 Q4	$1.32M	Buy	123,785 +29,000	+31%	+$351K	0.12%	142
2016 Q3	$1.03M	Hold	94,785	–	–	0.09%	163
2016 Q2	$642K	Hold	94,785	–	–	0.08%	184
2016 Q1	$442K	Buy	+94,785	New	+$463K	0.06%	161
2015 Q4	–	Sell	-64,785	Closed	-$572K	–	383
2015 Q3	$572K	Buy	64,785 +14,785	+30%	+$155K	0.09%	132
2015 Q2	$589K	Hold	50,000	–	–	0.09%	134
2015 Q1	$724K	Buy	+50,000	New	+$765K	0.1%	125

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Bailard's STML Position: Q4 2017 in Review

Bailard sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 64,600 shares — an estimated $717K sold.

Bailard first reported a position in STML in Q1 2015 and held it in 10 quarters. The position peaked at $1.32M in Q4 2016. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

Bailard reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Bailard sold 64,600 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $717K.
Bailard first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
Bailard's Stemline Therapeutics, Inc. position peaked at $1.32M in Q4 2016.
80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Bailard's 13F filing for Q4 2017, filed 8 Feb 2018.